{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:42:46Z","timestamp":1788982966370,"version":"build-2803163510"},"reference-count":83,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Adult-onset Still\u2019s disease (AOSD) is a systemic inflammatory disease of unknown etiology. Recent studies have demonstrated that the hallmark of AOSD is a cytokine storm, which is characterized by the excessive production of interleukin (IL)-1, IL-6, IL-18, tumor necrosis factor-\u03b1 (TNF-\u03b1), and interferon-\u03b3 (IFN-\u03b3), suggesting how pro-inflammatory cytokines play an important role in the pathogenesis of this disease. Actually, a certain proportion of patients (around 17\u201332%) with severe clinical symptoms achieves only partial remission or is resistant to both first-line corticosteroids and second-line DMARDs. These patients are defined as refractory AOSD patients, requiring higher dosage glucocorticoids, longer treatment duration, or the simultaneous introduction of immunosuppressive drugs, further leading to AOSD relapses. In this narrative review, we will analyze the latest literature data to unravel potential pathogenetic factors associated with specific patterns of AOSD disease or relapses in order to identify biomarkers that may guide clinical decisions, eventually leading to new therapeutic options.<\/jats:p>","DOI":"10.3390\/ijms222413320","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T01:28:11Z","timestamp":1639358891000},"page":"13320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Adult-Onset Still\u2019s Disease: Novel Biomarkers of Specific Subsets, Disease Activity, and Relapsing Forms"],"prefix":"10.3390","volume":"22","author":[{"given":"Beatrice","family":"Maranini","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ciancio","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0499-5773","authenticated-orcid":false,"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00296-009-1291-y","article-title":"Adult-onset Still\u2019s disease","volume":"30","author":"Bagnari","year":"2010","journal-title":"Rheumatol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still\u2019s disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still\u2019s disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","article-title":"Autoinflammatory disease reloaded: A clinical perspective","volume":"140","author":"Kastner","year":"2010","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38r","DOI":"10.1203\/PDR.0b013e31819dbd0a","article-title":"An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum","volume":"65","author":"McGonagle","year":"2009","journal-title":"Pediatr. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset Still\u2019s disease: New insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still\u2019s disease","volume":"13","author":"Jamilloux","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_9","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","article-title":"Adult-onset Still disease","volume":"22","author":"Fautrel","year":"2008","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10067-010-1553-9","article-title":"A case of refractory adult-onset Still\u2019s disease successfully controlled with tocilizumab and a review of the literature","volume":"29","author":"Praprotnik","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/1756-185X.12421","article-title":"Adalimumab in the treatment of refractory adult-onset Still\u2019s disease","volume":"20","author":"Lee","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/j.1756-185X.2010.01474.x","article-title":"A case of refractory adult-onset Still\u2019s disease treated with anakinra","volume":"13","author":"Lahiri","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10067-011-1735-0","article-title":"Is anti-TNF switching in refractory Still\u2019s disease safe and effective?","volume":"30","author":"Aikawa","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2016.02.010","article-title":"Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still\u2019s disease: Data from a large multicenter cohort","volume":"69","author":"Kalyoncu","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/art.1780300209","article-title":"Adult-onset Still\u2019s disease. Clinical course and outcome","volume":"30","author":"Cush","year":"1987","journal-title":"Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s10067-021-05722-7","article-title":"Identification of prognostic factors and construction of a nomogram for patients with relapse\/refractory adult-onset Still\u2019s disease","volume":"40","author":"Yin","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semarthrit.2010.12.006","article-title":"The evolution of adult-onset Still disease: An observational and comparative study in a cohort of 76 Italian patients","volume":"41","author":"Colina","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","article-title":"Writing a narrative biomedical review: Considerations for authors, peer reviewers, and editors","volume":"31","author":"Gasparyan","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.18632\/oncotarget.23098","article-title":"Impaired autophagic flux and its related inflammation in patients with adult-onset Still\u2019s disease","volume":"9","author":"Hsieh","year":"2018","journal-title":"Oncotarget"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hung, W.T., Hung, S.I., Chen, Y.M., Hsieh, C.W., Chen, H.H., Tang, K.T., Chen, D.Y., and Lan, T.H. (2021). The Association of ATG16L1 Variations with Clinical Phenotypes of Adult-Onset Still\u2019s Disease. Genes, 12.","DOI":"10.3390\/genes12060904"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1038\/emboj.2012.278","article-title":"Mechanism and functions of membrane binding by the Atg5-Atg12\/Atg16 complex during autophagosome formation","volume":"31","author":"Romanov","year":"2012","journal-title":"EMBO J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ng1954","article-title":"A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1","volume":"39","author":"Hampe","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/ng2032","article-title":"Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis","volume":"39","author":"Rioux","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrd.2018.149","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hung, W.T., Chen, Y.M., Hung, S.I., Chen, H.H., Gung, N.R., Hsieh, C.W., Tang, K.T., and Chen, D.Y. (2021). CARD8 SNP rs11672725 Identified as a Potential Genetic Variant for Adult-Onset Still\u2019s Disease. Life, 11.","DOI":"10.3390\/life11050382"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/14397595.2017.1422231","article-title":"Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still\u2019s disease: A multicenter retrospective study","volume":"28","author":"Kirino","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10067-020-05266-2","article-title":"Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still\u2019s disease","volume":"40","author":"Kim","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3899\/jrheum.181192","article-title":"Characteristics of Circulating Natural Killer Cells and Their Interferon-\u03b3 Production in Active Adult-onset Still Disease","volume":"46","author":"Shimojima","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"563335","DOI":"10.3389\/fimmu.2020.563335","article-title":"Circulating Neutrophil Extracellular Traps Signature for Identifying Organ Involvement and Response to Glucocorticoid in Adult-Onset Still\u2019s Disease: A Machine Learning Study","volume":"11","author":"Jia","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2009-06-225987","article-title":"An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes","volume":"115","author":"Curtale","year":"2010","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1038\/s41598-017-04086-w","article-title":"Upregulation of circulating microRNA-134 in adult-onset Still\u2019s disease and its use as potential biomarker","volume":"7","author":"Liao","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15676","DOI":"10.1038\/s41598-021-95028-0","article-title":"MicroRNA-223 inhibits neutrophil extracellular traps formation through regulating calcium influx and small extracellular vesicles transmission","volume":"11","author":"Liao","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics\u2014Challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_35","first-page":"113","article-title":"Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis","volume":"35","author":"Ciancio","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_36","first-page":"S99","article-title":"MicroRNA Expression Profile in Peripheral Blood Cells of Psoriatic Arthritis","volume":"33","author":"Ciancio","year":"2013","journal-title":"Clin. Drug Investig. Suppl. Suppl. Auckl."},{"key":"ref_37","first-page":"51","article-title":"The Role of Micro-RNAs in Rheumatic Diseases: An Update","volume":"51","author":"Ciancio","year":"2013","journal-title":"Innov. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6635925","DOI":"10.1155\/2021\/6635925","article-title":"Whole-Transcriptome RNA Sequencing Reveals Significant Differentially Expressed mRNAs, miRNAs, and lncRNAs and Related Regulating Biological Pathways in the Peripheral Blood of COVID-19 Patients","volume":"2021","author":"Li","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.55563\/clinexprheumatol\/4jx6zy","article-title":"Expression signature of inflammation-associated long non-coding RNAs in adult-onset Still\u2019s disease","volume":"39","author":"Yang","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"583513","DOI":"10.3389\/fimmu.2020.583513","article-title":"Roles of Interactions Between Toll-Like Receptors and Their Endogenous Ligands in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still\u2019s Disease","volume":"11","author":"Jung","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14737159.2019.1615449","article-title":"The role of damage-associated molecular pattern for pathogenesis and biomarkers in adult-onset Still\u2019s disease","volume":"19","author":"Jung","year":"2019","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Fujita, Y., Yago, T., Asano, T., Matsumoto, H., Matsuoka, N., Temmoku, J., Sato, S., Yashiro-Furuya, M., Suzuki, E., and Watanabe, H. (2021). Clinical relevance for circulating cold-inducible RNA-binding protein (CIRP) in patients with adult-onset Still\u2019s disease. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0255493"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-020-02263-3","article-title":"Elevated serum levels of checkpoint molecules in patients with adult Still\u2019s disease","volume":"22","author":"Fujita","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3899\/jrheum.120079","article-title":"Serum S100A8\/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still\u2019s disease","volume":"39","author":"Kim","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4049\/jimmunol.1800765","article-title":"A Multiparameter Flow Cytometry Analysis Panel to Assess CD163 mRNA and Protein in Monocyte and Macrophage Populations in Hyperinflammatory Diseases","volume":"202","author":"Thornton","year":"2019","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10067-015-3108-6","article-title":"Serum calprotectin--a promising diagnostic marker for adult-onset Still\u2019s disease","volume":"35","author":"Guo","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/rheumatology\/keaa135","article-title":"Serum sTREM-1 in adult-onset Still\u2019s disease: A novel biomarker of disease activity and a potential predictor of the chronic course","volume":"59","author":"Wang","year":"2020","journal-title":"Rheumatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/0008-5472.CAN-12-0938","article-title":"The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma","volume":"72","author":"Wu","year":"2012","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa031544","article-title":"Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia","volume":"350","author":"Gibot","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10067-012-1952-1","article-title":"Correlation of serum CX3CL1 level with disease activity in adult-onset Still\u2019s disease and significant involvement in hemophagocytic syndrome","volume":"31","author":"Kasama","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s13075-015-0773-4","article-title":"Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still\u2019s disease","volume":"17","author":"Han","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"46652","DOI":"10.1038\/srep46652","article-title":"Elevated circulating levels of the interferon-\u03b3-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still\u2019s disease","volume":"7","author":"Han","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1038\/s41598-019-44032-6","article-title":"Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR-4 ligand S100A8\/A9 in lymph nodes of patients with adult-onset Still\u2019s disease","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_54","first-page":"67","article-title":"The levels of CXCL12 and its receptor, CXCR4, as a biomarker of disease activity and cutaneous manifestation in adult-onset Still\u2019s disease","volume":"37","author":"Han","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"156890","DOI":"10.1155\/2012\/156890","article-title":"IL-18 Serum Level in Adult Onset Still\u2019s Disease: A Marker of Disease Activity","volume":"2012","author":"Colafrancesco","year":"2012","journal-title":"Int. J. Inflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.3899\/jrheum.140651","article-title":"Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still\u2019s disease","volume":"41","author":"Bae","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kudela, H., Drynda, S., Lux, A., Horneff, G., and Kekow, J. (2019). Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still\u2019s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol., 3.","DOI":"10.1186\/s41927-019-0053-z"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3899\/jrheum.170020","article-title":"Serum Levels of Interleukin 33 and Soluble ST2 Are Associated with the Extent of Disease Activity and Cutaneous Manifestations in Patients with Active Adult-onset Still\u2019s Disease","volume":"44","author":"Han","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1038\/s41598-021-91613-5","article-title":"The joint involvement in adult onset Still\u2019s disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile","volume":"11","author":"Ruscitti","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_60","first-page":"23","article-title":"Adult-onset Still\u2019s disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse","volume":"37","author":"Takakuwa","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbspin.2017.05.011","article-title":"New Markers for Adult-Onset Still\u2019s Disease","volume":"85","author":"Mitrovic","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ruscitti, P., Cipriani, P., Masedu, F., Iacono, D., Ciccia, F., Liakouli, V., Guggino, G., Carubbi, F., Berardicurti, O., and Di Benedetto, P. (2016). Adult-onset Still\u2019s disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med., 14.","DOI":"10.1186\/s12916-016-0738-8"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00296-011-1801-6","article-title":"Therapeutic responses and prognosis in adult-onset Still\u2019s disease","volume":"32","author":"Kim","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s10067-010-1516-1","article-title":"Clinical features and prognosis in adult-onset Still\u2019s disease: A study of 104 cases","volume":"29","author":"Kong","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-020-00207-2","article-title":"Role of platelet biomarkers in inflammatory response","volume":"8","author":"Chen","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/art.37921","article-title":"Metabolic profiling predicts response to anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis","volume":"65","author":"Kapoor","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Chen, D.Y., Chen, Y.M., Chien, H.J., Lin, C.C., Hsieh, C.W., Chen, H.H., Hung, W.T., and Lai, C.C. (2016). Metabolic Disturbances in Adult-Onset Still\u2019s Disease Evaluated Using Liquid Chromatography\/Mass Spectrometry-Based Metabolomic Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168147"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3389\/fimmu.2020.02112","article-title":"Urinary Proteomics Identifying Novel Biomarkers for the Diagnosis of Adult-Onset Still\u2019s Disease","volume":"11","author":"Sun","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"719544","DOI":"10.3389\/fimmu.2021.719544","article-title":"Interleukin-18 Is a Potential Biomarker to Discriminate Active Adult-Onset Still\u2019s Disease From COVID-19","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e20201707","DOI":"10.1084\/jem.20201707","article-title":"Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients","volume":"218","author":"Rodrigues","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"654811","DOI":"10.3389\/fimmu.2021.654811","article-title":"Serum Heparin-Binding Protein as a Potential Biomarker to Distinguish Adult-Onset Still\u2019s Disease From Sepsis","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e026527","DOI":"10.1136\/bmjopen-2018-026527","article-title":"Usefulness of the heparin-binding protein level to diagnose sepsis and septic shock according to Sepsis-3 compared with procalcitonin and C reactive protein: A prospective cohort study in China","volume":"9","author":"Zhou","year":"2019","journal-title":"BMJ Open"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Di Benedetto, P., Cipriani, P., Iacono, D., Pantano, I., Caso, F., Emmi, G., Grembiale, R.D., Cantatore, F.P., Atzeni, F., and Perosa, F. (2020). Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still\u2019s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235326"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/keaa368","article-title":"Neutrophil-derived lipocalin-2 in adult-onset Still\u2019s disease: A novel biomarker of disease activity and liver damage","volume":"60","author":"Jia","year":"2021","journal-title":"Rheumatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"560744","DOI":"10.3389\/fimmu.2020.560744","article-title":"The Role of RIPK1\/3 in Adult Onset Still\u2019s Disease Patients With Liver Damage: A Preliminary Study","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still\u2019s disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"Junge","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for Treatment of Adult-Onset Still\u2019s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): Phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: A randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.berh.2012.07.002","article-title":"Biological treatment in adult-onset Still\u2019s disease","volume":"26","author":"Pouchot","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_82","first-page":"840","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14712598.2019.1652591","article-title":"Biologics for the treatment of adult-onset still\u2019s disease","volume":"19","author":"Yoo","year":"2019","journal-title":"Expert. Opin. Biol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/24\/13320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:45:27Z","timestamp":1760168727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/24\/13320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,11]]},"references-count":83,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ijms222413320"],"URL":"https:\/\/doi.org\/10.3390\/ijms222413320","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,11]]}}}